Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30944657 | 0.98 | CA12 (0.35) | CA12CA1CA2CA9 | |
| Trifluoroacetic Acid SCHEMBL30944679 | 0.89 | L3MBTL1 (0.35) | CA12CA1CA2CA9 | |
| SCHEMBL3660695 | 0.85 | CA12 (0.35) | CA12CA1CA2CA9 | |
| SCHEMBL12563116 | 0.78 | CA12 (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL18710382 | 0.74 | CA12 (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL27514956 | 0.69 | IDO1 (0.37) | CA12CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL31078519 | 0.68 | IDO1 (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL27276961 | 0.67 | NPBWR1 (0.31) | — | |
| SCHEMBL1725269 | 0.66 | CA12 (0.55) | CA12CA1CA2CA9 | |
| SCHEMBL1488644 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-10-10 | — | — | US | claimed |
| EP-4608821-A1 | PHARMACEUTICAL COMPOUNDS AS PARP7 AND/OR PARP1 INHIBITORS | Duke Street Bio Limited (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250074897-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2025-03-06 | — | — | US | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-4423078-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240190844-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| WO-2024115465-A1 | PHARMACEUTICAL COMPOUNDS AS PARP7 AND/OR PARP1 INHIBITORS | Duke Street Bio Limited (GB) | 2024-06-06 | — | — | WO | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| WO-2022247839-A1 | PARP7 INHIBITOR | 山东轩竹医药科技有限公司 | 2022-12-01 | — | — | WO | disclosed |
| WO-2022166749-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海湃隆生物科技有限公司 | 2022-08-11 | — | — | WO | disclosed |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2019-10-31 | — | — | US | disclosed |
| CN-104277004-B | Prepare method and its intermediate of pyridazinone compound | 住友化学株式会社 | 2016-08-24 | — | — | CN | disclosed |
| EP-2220073-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009063244-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-05-22 | — | — | WO | disclosed |
| EP-0934254-A1 | PRODUCTION OF PYRIDAZINE HERBICIDES | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998017632-A1 | PRODUCTION OF PYRIDAZINE HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190844-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | CA12 4842/4885CA1 4884/4885CA2 4795/4885 |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | CA12 4842/4885CA1 4884/4885CA2 4795/4885 |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | CA12 4842/4885CA1 4884/4885CA2 4795/4885 |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | CA12 4842/4885CA1 4884/4885CA2 4795/4885 |
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | CA12 4603/4885CA1 4820/4885CA2 4809/4885 |
| US-20250074897-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | CA12 4842/4885CA1 4884/4885CA2 4795/4885 |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | CA12 4842/4885CA1 4884/4885CA2 4795/4885 |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | CA12 4603/4885CA1 4820/4885CA2 4809/4885 |
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | PARP1, PARP2, PARP11 | CA12 4518/4885CA1 4252/4885CA2 4150/4885 |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | CA12 4842/4885CA1 4884/4885CA2 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.